Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Up Almost 11 Percent on BioReliance Sale, EPS Performance

NEW YORK (GenomeWeb News) — Shares in Invitrogen were up nearly 10.5 percent at $66.73 in mid-afternoon trading after the company reported yesterday it would sell its flagging BioReliance business, and that its fourth-quarter earnings per share beat Wall Street expectations.
 
As GenomeWeb News reported this morning, Invitrogen said it plans to sell the BioReliance unit to Avista Capital Partners for $210 million as part of Invitrogen’s ongoing plan to better organize its acquired components, the companies said late yesterday.  
 
Separately yesterday, Invitrogen reported weak fourth-quarter revenue growth as R&D spending decreased 7.6 percent and net income dropped 300 percent on a variety of one-time charges. However, earnings per share beat analysts' estimates.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.